A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

NCT06456567 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor business decision

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Telitacicept
DRUG: Placebo

Sponsor

Vor Biopharma